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OBJECTIVE—Adiponectin is an adipocyte-derived protein that
acts to reduce insulin resistance in the liver and muscle and also
inhibits atherosclerosis. Although adiponectin reportedly en-
hances AMP-activated protein kinase and inhibits tumor necrosis
factor- action downstream from the adiponectin signal, the
precise physiological mechanisms by which adiponectin acts on
skeletal muscles remain unknown.
RESEARCH DESIGN AND METHODS—We treated murine
primary skeletal muscle cells with recombinant full-length hu-
man adiponectin for 12 h and searched, using two-dimensional
electrophoresis, for proteins upregulated more than threefold by
adiponectin compared with untreated cells.
RESULTS—We found one protein that was increased 6.3-fold
with adiponectin incubation. MALDI-TOF (matrix-assisted laser
desorption/ionizationtop of flight) mass spectrometric analysis
identiﬁed this protein as ferritin heavy chain (FHC). When
murine primary skeletal muscle cells were treated with adiponec-
tin, IB- phosphorylation was observed, suggesting that adi-
ponectin stimulates nuclear factor (NF)-B activity. In addition,
FHC upregulation by adiponectin was inhibited by NF-B inhib-
itors. These results suggest NF-B activation to be involved in
FHC upregulation by adiponectin. Other NF-B target genes,
manganese superoxide dismutase (MnSOD) and inducible nitric
oxide synthase (iNOS), were also increased by adiponectin
treatment. We performed a reactive oxygen species (ROS) assay
using CM-H2DCFDA ﬂuorescence and found that ROS-reducing
effects of adiponectin were abrogated by FHC or MnSOD small-
interfering RNA induction.
CONCLUSIONS—We have demonstrated that adiponectin up-
regulates FHC in murine skeletal muscle tissues, suggesting that
FHC elevation might partially explain how adiponectin protects
against oxidative stress in skeletal muscles. Diabetes 58:61–70,
2009
A
dipocytes have been recognized to secrete a
variety of proteins, such as tumor necrosis
factor (F)-, adipsin, plasminogen activator
inhibitor-1, leptin, resistin, and adiponectin.
These proteins are termed adipokines and are likely to
physiologically exert a variety of hormonal actions (1).
Among these proteins, adiponectin is exclusively ex-
pressed in adipose tissue and consists of an NH2-terminal
collagenous domain and a COOH-terminal globular do-
main (2). Adiponectin belongs to the soluble collagen
superfamily and has structural homology with collagens
VIII and X, complement factor C1q (3), and the TNF family
(2,4). Circulating adiponectin is extremely abundant (15
g/ml), and adiponectin forms various oligomeric com-
plexes, including low (LMW), medium (MMW), and high
(HMW) molecular weight species. Adiponectin exerts an-
tidiabetes effects on muscles and the liver through AMP-
activated protein kinase activation (5) and antiath-
erosclerotic effects by inhibiting monocyte adhesion to
endothelial cells and lipid accumulation into macrophages
(6,7). Thus, adiponectin increases glucose uptake and fatty
acid oxidation in muscles via the type 1 adiponectin
receptor (8), and decreases hepatic gluconeogenesis via
the type 2 adiponectin receptor (8,9). On the other hand,
nuclear factor (NF)-B but not AMP-activated protein
kinase activity was demonstrated to be enhanced by MMW
or HMW adiponectin in muscles (10). According to recent
studies (9–14), HMW adiponectin appears to be more
important for the antidiabetes and antiatherosclerotic
effects than the other two oligomeric complexes. Though
the physiological role of HMW adiponectin in improving
insulin resistance or reducing oxidative stress is clearly
signiﬁcant, the precise mechanisms by which adiponectin
acts on skeletal muscles remain unknown.
Therefore, in the present study, we investigated adi-
ponectin function in primary cultured skeletal muscle cells
by comparing protein expressions in untreated cells using
two-dimentional electrophoresis. A marked increase in
FHC protein was observed with adiponectin incubation.
FHC is one of two subunits of ferritin, the other being
ferritin light chain (FLC) (15), and has ferroxidase activity,
which is required for iron sequestration (16). FHC was
reported to suppress reactive oxygen species (ROS) pro-
duction (17), which may explain the ROS-reducing effects
of adiponectin. FHC upregulation followed by an en-
hanced ROS-reducing effect is suggested to be a novel
mechanism by which adiponectin acts directly against
oxidative stress.
RESEARCH DESIGN AND METHODS
Cell culture and chemicals. Murine primary cultured skeletal muscle cells
were purchased from Cell Garage (Tokyo, Japan) in cultured ﬂasks, and
maintained in DMEM containing 10% fetal bovine serum (FBS). We switched
the medium to DMEM containing 2% horse serum, which promotes differen-
tiation of myocytes into myotubes, and continued the incubation for 5 days
before the experiments. Human umbilical vein endothelial cells (HUVECs)
were purchased from Cambrex (Baltimore, MD) as cryopreserved cells. After
thawing, the cells were plated in collagen-coated culture ﬂasks and cultured to
conﬂuence in EBM-2 medium (Lonza, Walkersville, MD) containing the
indicated ligands, 2% FBS, and antibiotics (BulletKit EGM-2, cat. no. CC-3162).
C2C12 myoblasts were maintained in DMEM containing 10% FBS at 37°C in 5%
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DIABETES, VOL. 58, JANUARY 2009 61CO2. After the C2C12 cells reached subconﬂuence, differentiation was induced
by treatment with DMEM containing 5% horse serum for 7 days, at which time
formation of myotubes was maximal. The following chemicals were pur-
chased: H89 from Seikagaku (Tokyo, Japan); NF-B inhibitor, NF-B SN50,
and BAY11-7082 from Biomol Research Laboratories (Plymouth Meeting, PA);
forskolin, TNF-, palmitate, and iron (II) sulfate heptahydrate from Sigma-
Aldrich (St. Louis, MO); human recombinant adiponectin from R&D Systems
(Minneapolis, MN); human recombinant globular adiponectin from BioVendor
Laboratory Medicine (Modrice, Czech Republic); and 4-hydroxynonenal from
Calbiochem (San Diego, CA). Fatty acid solution was prepared by a method
described previously (18).
Two-dimensional electrophoresis. A total of 3.0  10
6 murine primary
cultured skeletal muscle cells were dissolved in lysis solution (7 mol/l urea, 2
mol/l thiourea, 4% CHAPS, 0.5% IPG buffer, 18 mmol/l dithiothreitol, and 2
mmol/l phenylmethanesulphonylﬂuoride, pH 8.5). Impurities such as salts,
lipids, detergent, and nucleic acids were then removed from samples using a
two-dimensional clean-up kit (Amersham Pharmacia Biotech, Amersham,
U.K.). Samples were redissolved in rehydration solution and centrifuged at
24,000 rpm for 20 min at 10°C, and insoluble substances were removed. Using
450 l of solution corresponding to 400 g of murine primary cultured skeletal
muscle cell protein, two-dimensional gel electrophoresis was performed
according to the manufacturer’s instructions (Amersham Pharmacia Biotech).
The gels were Coomassie brilliant blue stained using PhastGel Blue R-350.
Colloidal Coomassie blue–stained gels were scanned using a GS-800 cali-
brated densitometer (Bio-Rad Laboratories, Hercules, CA), and gel images
were analyzed using PDQuest 2D-Image-Analysis software (version 7.3; Bio-
Rad Laboratories). For this analysis, three independent sets consisting of a
control sample gel and an adiponectin-treated sample gel were prepared. For
a between-gel comparison, a set of spot-generation conditions was used. To
analyze the proteins, we ﬁrst chose one protein signal to assure that the
number of proteins, with signals more intense than that initially chosen, would
be 1,500. Then, we analyzed only these 1,500 protein signals. The computer
allowed automatic detection and quantiﬁcation of protein spots, as well as
matching between the control and adiponectin-treated gels. Routine statistical
analysis available within the software package was used to identify up- or
down-expressed spots. The differentially expressed protein spots were iden-
tiﬁed by quantitative comparisons with control gels.
Identiﬁcation of proteins upregulated by adiponectin. Protein spots of
interest were excised from the gels and subjected to matrix-assisted laser
desorption/ionizationtop of flight (MALDI-TOF) mass spectrometry. In-gel
digestion of the individual protein spots was done by the following method.
Pieces of gel were destained using 200 l of 50 mmol/l ammonium bicarbonate
in 50% acetonitrile, dehydrated in 200 l of acetonitrile, and then completely
dried by vacuuming and centrifuging. The samples were then allowed to
expand in digestion buffer containing 100 mmol/l ammonium bicarbonate, 20
g/ml of trypsin (Promega, Madison, WI), and 0.1% octyl 	-D-glucopyranoside
(Sigma-Aldrich) at 4°C. After a 30-min incubation, the samples were incubated
overnight at 37°C. Peptides were then extracted twice using 0.1% triﬂuoro-
acetic acid in 30% acetonitrile with sonication. The peptide solution was
vacuum concentrated until it had decreased to 10 l and desalted according to
the manufacturer’s protocol. An AXIMA-CFR model MALDI-TOF mass spec-
trometer (Shimadzu, Kyoto, Japan) was used for mass analysis of tryptic
peptide mixtures. Peptides were identiﬁed with the Mascot search program
(Matrix Science, London, U.K.).
Western blotting and quantitative PCR. Western blotting was performed
as previously described (19). Brieﬂy, after incubation with the indicated
chemicals, primary cultured skeletal muscle cells were washed with ice-cold
PBS, lysed in ice-cold lysis buffer, and then centrifuged at 14,000g for 10 min
at 4°C. Supernatants including tissue protein extracts were resolved on 10%
SDS-PAGE, followed by electrophoretic transfer to a nitrocellulose mem-
brane. Membranes were incubated for1ha troom temperature with the
appropriate primary antibody. Commercial antibodies against phosphor–
inhibitor of B- (IB-), intercellular adhesion molecule (ICAM)-1 FHC FLC,
p65 NF-B (Santa Cruz Biotechnology, Santa Cruz, CA), and IB- (Cell
Signaling Technology, Palo Alto, CA) were purchased. After blotting with the
indicated secondary antibody, detection was performed using an ECL chemi-
luminescent kit (Amersham Pharmacia Biotech), according to the manufac-
turer’s instructions. Quantitations were performed using a Molecular Imager
(Bio-Rad Laboratories). cDNA was synthesized from the puriﬁed total RNA
using a reverse transcriptase kit (Amersham Pharmacia Biotech), according to
the manufacturer’s instructions. For quantitative analysis of FHC, manganese
superoxide dismutase (MnSOD), and inductible nitric oxide synthase (iNOS),
we conducted real-time PCR using an ABI PRISM model 7000 (Applied
Biosystems, Foster City, CA), according to the manufacturer’s instructions.
The primer sets and probes for murine FHC (assay ID: Mm00850707_g1),
murine MnSOD (assay ID: Mm00449726_m1), and murine iNOS (assay ID:
Mm00440485_m1) were purchased. Nuclear protein extracts were prepared by
separating the cell pellet into two compartments (i.e., the nucleus and the
cytosol), as previously described (18).
Small-interfering RNA reagents and transfection. C2C12 myotubes were
transfected with small-interfering (siRNA) against FHC (ID 158606, 66945),
MnSOD (ID 152022, 71294), and iNOS (ID 156550, 68442) (Applied Biosys-
tems) using the transfection reagent (AM4510; Applied Biosystems), following
the manufacturer’s protocol. As the control, we utilized the commercially
available siRNA control nonsilencing sequence (4611G; Applied Biosystems).
The cells were used for experiments 48 h after siRNA transfection.
Generation and transfection of recombinant adenoviruses expressing
FHC and adiponectin. A full-length mouse FHC cDNA was isolated from
mouse hepatic RNA by reverse-transcriptase PCR. The oligonucleotide se-
quences used for PCR were as follows: coding strand, 5
-ACCATGACCAC-
CGCGTCTCCCTCGCAAGTG-3
; noncoding strand, 5
-AGCTTAGCTCTCATCA
CCGTGTCCCAGGGT-3
. The cDNA was subcloned into TA vectors, pCRII
(Invitrogen Life Technologies, CA), sequenced to conﬁrm their identities,
and were observed to have no unexpected mutations. Adenovirus-express-
ing recombinant FHC was prepared by homologous recombination of the
expression cosmid cassettes containing the corresponding cDNAs and the
parental adenovirus genome, as described previously (20). Adenovirus-
expressing recombinant adiponectin was prepared as reported previously
(21). For adenovirus-mediated transfection, cultured cells were incubated
f o r2hi n37°C with DMEM containing the adenovirus-expressing LacZ or
FHC, and the growth media were then added. Experiments were performed
3 days after transfection. Mice were treated with recombinant adenovirus,
expressing LacZ or adiponectin, by systemic injection into the tail vein.
Assay of intracellular cAMP contents. cAMP was measured in murine
primary cultured skeletal muscle cells using a direct enzyme immunoassay kit
according to the instructions provided by the manufacturer (Amersham
Pharmacia Biotech). Brieﬂy, cell lysates (100 l) were transferred to a new
96-well microplate coated with donkey anti-rabbit IgG. After addition of 100 l
of rabbit anti-cAMP serum to each well, the microplate contents were gently
mixed and incubated at 4°C for 2 h. Then, after addition of 50 l of cAMP
peroxidase conjugate to each well, the microplates were gently agitated and
incubated at 4°C for 60 min. We aspirated and washed each well four times
with 400 l of washing buffer and blotted the plate on tissue paper to remove
any residual liquid. Next, we immediately dispensed 150 l of enzyme
substrate into each well, followed by mixing on a microplate shaker for
exactly 60 min at room temperature. To halt the reaction, we added 100 lo f
1.0 mol/l sulfuric acid to each well. The optical density was determined in a
plate reader at 450 nm.
Detection of intracellular ROS production. Intracellular ROS produc-
tion was monitored by ﬂow cytometry (Becton Dickinson, Franklin Lakes,
NJ) using 5-(and 6)-chloromethyl-2
,7
-dichlorodihydroﬂuorescein diac-
etate, acetyl ester (CM-H2DCFDA). Cells were stimulated with the indi-
cated reagents in culture dishes and incubated for 24 h. Then, these cells
were washed twice in PBS, followed by addition of 10 mol/l CM-
H2DCFDA in PBS, and ﬁnally placed in the dark at 37°C for 1 h. The cells
were washed once, harvested, and suspended in 500 l PBS. Dead cells
were excluded by adding 10 mol/l propidium iodide, a nuclear stain to
which viable cells are impermeable. ROS levels were measured by ﬂow
cytometrically by determining the mean ﬂuorescent intensity relative to
that of the control group. Using this method, we were able to measure not
only H2O2 but also hydroxy radical (
OH) or peroxynitrite (ONOO
). As it
was important to measure hydroxy radicals (OH), generated by the Fenton
reaction, we adopted this method.
Animals. Nine-week-old male mice (C57BL/KsJ, n  14) were purchased from
Clea Japan (Osaka, Japan). After a 2- to 3-day acclimatization period, all mice
were maintained on a 12:12-h light-dark cycle, fed a standard rodent diet ad
libitum, and given unlimited access to water. The mice were divided into a
LacZ-transferred group (control construct) and an adiponectin-transferred
group (adiponectin construct), and adenovirus-mediated gene transfer was
performed. Before they were killed, the animals were fasted for 8 h. Three
days after virus infection, increased serum adiponectin levels were conﬁrmed
using both a mouse/rat adiponectin ELISA kit (Otsuka, Tokushima, Japan) and
immunoblot analysis with anti-murine adiponectin antibody (Chemicon Inter-
national, Temecula, CA). Then, total hind limbs were removed and immedi-
ately homogenized with a Polytron homogenizer in six volumes of
solubilization buffer. Extracts were centrifuged at 15,000g for 30 min at 4°C,
and the supernatants were used as samples for immunoblotting with anti-FHC
antibody.
Statistical analysis. All data were expressed as means  SE. The statistical
signiﬁcance of differences between groups was assessed with the unpaired
Student’s t test using Stat View software (version 5.01; SAS Institute, Cary,
NC). A P value 
0.05 was considered statistically signiﬁcant.
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Identiﬁcation of proteins upregulated by adiponectin.
We treated murine primary cultured skeletal muscle cells
with recombinant full-length human adiponectin, which
was expressed in the mouse myeloma cell line NS0 and
puriﬁed, and then we searched, using two-dimensional
electrophoresis, for proteins upregulated more than three-
fold by adiponectin as compared with untreated cells. As
conﬁrmed by immunoblotting under nonreducing condi-
tions (Fig. 1E), the adiponectin species used in this
experiment may be atypical because these were essen-
tially mixtures of the HMW and LMW isoforms of adi-
ponectin, with little of the MMW form. The gels were
stained with Coomassie brilliant blue (Fig. 1A) and
scanned using a GS-800 calibrated densitometer, and gel
images were analyzed. We selected 1,500 protein signals.
Among these, only one protein was increased (6.3-fold)
with adiponectin incubation. The protein spots in the
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FIG. 1. Effects of incubation with HMW adiponectin on primary cultured skeletal muscles. Primary cultured murine skeletal muscles were
incubated for 12 h in the presence () or absence () of adiponectin (25 g/ml). A: Whole images of Coomassie brilliant blue–stained gels for
two-dimensional electrophoresis in the absence (left) or presence (right) of adiponectin. B: Magniﬁed images of two-dimensional electrophoresis
revealing a spot apparently altered by adiponectin treatment (arrows). Three two-dimensional electrophoresis sets yielded similar results. C–E:
After incubation with the indicated ligands, primary cultured skeletal muscle cells were lysed in ice-cold lysis buffer and centrifuged at 14,000g
for 10 min at 4°C. Supernatants including tissue protein extracts were resolved on 10% SDS-PAGE, followed by electrophoretic transfer to a
nitrocellulose membrane. Membranes were incubated for1ha troom temperature with antibody against mouse FHC (C) or FLC (D). E: The
recombinant full-length human adiponectin, which was expressed in a mouse myeloma cell line NS0, was resolved on 7.5% SDS-PAGE under
nonreducing conditions and investigated by immunoblotting with anti-adiponectin antibody. After blotting with the indicated secondary antibody,
detection was performed using an electrochemiluminescence chemiluminescent kit according to the manufacturer’s instructions. Representative
data from four independent experiments are presented. *Signiﬁcant difference (P < 0.05) relative to FHC expression in control cells.
**Signiﬁcant difference (P < 0.05) relative to FHC expression with 25 g/ml of adiponectin. N.S., not signiﬁcant relative to control cells in the
absence of adiponectin.
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the arrows in the magniﬁed ﬁgure (Fig. 1B). We excised
the protein spot from the gel (Fig. 1B, right panel) and
identiﬁed four peptides, which were matched to FHC
sequences (a.a.54–63, a.a.109–143, a.a.147–156, and
a.a.158–172) using MALDI-TOF-MS analysis. The Score
and Expect of the Mascot Search were 76 and 0.0022,
respectively, both of which are highly deﬁnitive for FHC.
As shown in Fig. 1C, FHC protein expressions were
signiﬁcantly increased in an adiponectin concentration–
dependent manner but were unaffected by incubation with
the same concentration of type I collagen or recombinant
globular adiponectin, suggesting FHC upregulation to be
speciﬁc to the multimer formation of adiponectin. Next,
we assessed whether the expression of FLC is also upregu-
lated by adiponectin. However, FLC expression was not
altered (Fig. 1D).
NF-B activation is involved in FHC upregulation by
adiponectin. As FHC was reported to be transcriptionally
upregulated in response to NF-B activation (22), we next
investigated whether adiponectin enhances NF-B activity
in primary skeletal muscle cells. The NF-B bound to
IB- is generally located in the cytosol before activation.
In response to stimuli, IB- proteins are degraded, a
process controlled by IB- phosphorylation, resulting in
nuclear translocation of NF-B and subsequent activation
of NF-B target gene transcription. When the cells were
incubated with adiponectin, phosphorylation of IB-
(Fig. 2A, upper panel, lanes 1 and 2) and a decrease in
total IB- (Fig. 2A, lower panel, lanes 1 and 2) were
observed, revealing that adiponectin actually stimulates
NF-B activation. The IB- phosphorylation required at
least3ho fincubation, suggesting that secondary effects
might be involved in adiponectin-induced IB- phosphor-
ylation. NF-B SN50, an inhibitor of NF-B translocation
into the nucleus, did not affect the I-B phosphorylation by
adiponectin (Fig. 2A, lanes 5 and 6), whereas it was
abolished by incubation with BAY11-7082, an inhibitor of
IB- phosphorylation (Fig. 2A, lanes 3 and 4). To conﬁrm
that SN50 inhibits NF-B translocation to the nucleus, we
separated the myocyte-lysates into two compartments
(i.e., nuclear extracts and cytosol) and performed immu-
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FIG. 2. Effects of IB/NF-B inhibitor on FHC in murine primary cultured skeletal muscle cells. Primary cultured skeletal muscle cells were
pretreated with 100 mol/l BAY11-7082 or 50 g/ml NF-B SN50 at 1 h before the cells were incubated with 40 g/ml of adiponectin for 12 h. Cells
were lysed in ice-cold lysis buffer and centrifuged at 14,000g for 10 min at 4°C. Supernatants including tissue protein extracts were subjected to
SDS-PAGE. Transferred membranes were incubated for1ha troom temperature with antibody against phosphor–IB- (A, upper panel), IB-
(A, lower panel), p65 NF-B( B), and FHC (C and D). After blotting with the indicated secondary antibody, detection was performed using an
electrochemiluminescence chemiluminescent kit. Representative data (one sample each for A and B; two each for C and D) from four independent
experiments (two samples for each experiment) are presented. Values are means  SE. *Signiﬁcant difference (P < 0.05) relative to IB-
phosphorylation (A, upper panel), total IB- (A, lower panel), p65 NF-B( B), or FHC expression (C and D) of control cells in the absence of
adiponectin. **Signiﬁcant difference (P < 0.05) relative to IB- phosphorylation (A, upper panel) or total IB- (A, lower panel) of paired
control cells in the absence of adiponectin (lane 5). N.S., not signiﬁcant relative to IB- phosphorylation (A, upper panel), total IB- (A, lower
panel), p65 NF-B( B), or FHC expression (C and D) of paired control cells in the absence of adiponectin.
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Fig. 2B, increases in nuclear NF-B proteins were ob-
served with adiponectin incubation (Fig. 2B, lane 2),
indicating translocation of the activated NF-B into the
nucleus, whereas no signiﬁcant translocation of NF-B
proteins was observed when both adiponectin and SN50
were present (Fig. 2B, lane 6). In addition, FHC upregula-
tion by adiponectin was completely abolished by NF-B
SN50 (Fig. 2C) or BAY11-7082 (Fig. 2D), indicating that
FHC was upregulated by adiponectin via an NF-B–depen-
dent pathway. Taking into consideration the reported
upregulation of FHC by cAMP via a proximal cis-acting
element containing the CCAAT motif (23), we further
examined whether FHC is regulated by a cAMP–protein
kinase A (PKA)-dependent pathway. When incubated
with adiponectin, cAMP levels inside primary cultured
muscle cells were increased by 2.8-fold with FHC upregu-
lation (Fig. 3, lane 2). Unexpectedly, H89, a PKA inhibitor,
failed to block this FHC upregulation by adiponectin (Fig.
3, lane 4). Furthermore, forskolin increased cAMP levels
in these cells without FHC upregulation (Fig. 3, lane 2).
These results suggest that cAMP elevation in response
to adiponectin treatment was not associated with FHC
upregulation.
The effects of adiponectin, TNF-, and free fatty
acids on NF-B target gene in HUVECs. To investigate
whether adiponectin increases FHC in other types of
cultured cells, we further examined the NF-B activation
of HUVECs. When HUVECs were treated with adiponectin,
ICAM-1, which is primarily regulated by the NF-B tran-
scription factor, was slightly, but signiﬁcantly, increased
(Fig. 4A). In contrast, TNF- markedly increased ICAM-1
expression (Fig. 4B). These ICAM-1 inductions by adi-
ponectin or TNF- were both inhibited by the addition of
BAY 11-7082. These results suggested that TNF- upregu-
lated ICAM-I via an NF-B–dependent pathway in
HUVECs to a far greater extent than adiponectin. In
addition, we examined the synergistic effects of adiponec-
tin and TNF- on ICAM-1 expression. Unexpectedly, the
induction of ICAM-1 by TNF- was inhibited by further
addition of adiponectin (Fig. 4C), indicating that TNF-
and adiponectin antagonized each other via the signaling
pathways of these agents. This phenomenon, which was
reported previously (7,24), was also observed in the ac-
tions of adiponectin and palmitate on ICAM-1 expression.
Next, we examined the effects of these NF-B activators
on FHC expression in HUVECs. Although FHC expression
was slightly increased by TNF-, neither adiponectin nor
palmitate treatment produced signiﬁcant increases (Fig.
4D). Taken together, these observations indicated that
induction of FHC by adiponectin does not occur in
HUVECs despite the NF-B activation, presumably due to
the minor effect of adiponectin on NF-B activation.
Recombinant FHC reduces ROS production induced
by oxidative stress. To investigate the cytoprotective
effects of FHC against forms of damage mediated by
oxidative stresses or inﬂammatory cytokines, we trans-
fected adenovirus expressing recombinant FHC into
HUVECs and C2C12 myocytes. As the murine primary
cells exhibited susceptibility to adenovirus infection, we
performed this experiment with C2C12 myotubes. Before
the ROS assay, we conﬁrmed recombinant FHC to be
overexpressed by immunoblotting using anti-murine FHC
antibodies. With overexpression of recombinant FHC, 13
and 28% reductions in relative ROS accumulations were
observed in HUVECs and C2C12 myotubes, respectively
(Fig. 5). In addition, FHC had a major effect on reducing
ROS accumulation induced by various forms of oxidative
stress (i.e., 26% [Fe
2], 18% [TNF-], and 25% [high glu-
cose] in HUVECs; and 26% [(Fe
2], 20% [TNF-], and 49%
[4-hydroxynonenal] in C2C12 myotubes), indicating that
FHC exerts cytoprotective effects by reducing the ROS
accumulation induced by various oxidative stresses. When
these cells were treated with adiponectin, ROS-reducing
effects, which were similar to those obtained with FHC
overexpression, were also observed (data not shown).
Taken together, these ﬁndings indicated FHC upregulation
by adiponectin in skeletal muscle cells to at least partially
explain the ROS-reducing effects of adiponectin.
Increased expression of NF-B target genes with
adiponectin incubation and their contributions to the
ROS-reducing effects of adiponectin. We further inves-
tigated NF-B target gene expressions (e.g., MnSOD and
iNOS) by quantitative PCR. As shown in Fig. 6, these
proteins (FHC, MnSOD, and iNOS) were similarly upregu-
lated by adiponectin incubation (3.6-, 1.6-, and 5.1-fold,
respectively, in skeletal muscle cells and 4.3-, 1.8-, and
3.5-fold, respectively, in C2C12 myotubes). No MnSOD
protein was identiﬁed on our two-dimensional electro-
phoresis search for proteins upregulated more than three-
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FIG. 3. Effects of recombinant human adiponectin on cAMP content of
murine primary skeletal muscle cells. Primary skeletal muscle cells,
cultured in 96-well plates, were exposed to 50 g/ml of adiponectin and
5 mol/l forskolin for 12 h. Adiponectin-treated cells were also pre-
treated with 1 mol/l H89, a PKA inhibitor, for 1 h before the addition
of adiponectin. The cAMP assay was performed according to the
manufacturer’s instructions. Cell lysates from primary cultured skele-
tal muscle cells were subjected to SDS-PAGE, followed by electro-
phoretic transfer to a nitrocellulose membrane. Membranes were
incubated for1ha troom temperature with antibody against mouse
FHC. Detection was performed using an electrochemiluminescence
chemiluminescent kit according to the manufacturer’s instructions.
Representative results from four independent experiments are pre-
sented. Values are means  SE. *Signiﬁcant difference (P < 0.05)
relative to control cells in the absence of ligands (lane 1). N.S.; not
signiﬁcant relative to paired control cells in the absence of forskolin
(lane 1) or H89 (lane 3).
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identify iNOS in two-dimensional electrophoresis was not
entirely clear, the minute amounts of iNOS proteins in
skeletal muscles made this form of analysis impractical
(25). To clarify the relevance of the observed increase in
all three proteins to the changes in ROS, we investigated
the ROS levels in C2C12 myotubes, in which the expres-
sions of these three proteins were inhibited by induction
of siRNAs. As shown in Fig. 7, under the condition in
which no signiﬁcant increases in the three gene products
were observed with adiponectin incubation, we investi-
gated adiponectin-induced changes in ROS accumulation.
When FHC siRNAs were induced, we observed a marked
decrease in the ROS-reducing effects of adiponectin incu-
bation. On the other hand, there was no signiﬁcant change
in ROS accumulation with iNOS siRNA induction, while
a slight but signiﬁcant decrease was observed with
MnSOD siRNA induction. These results suggest that in-
creased FHC expression has a major impact on ROS
accumulation; however, this increase does not explain the
entire ROS-reducing effect of adiponectin.
Increased serum adiponectin upregulates FHC in
skeletal muscles in vivo. To further conﬁrm the FHC
upregulation by adiponectin in in vivo experiments, we
prepared mice expressing recombinant adiponectin by
systemic adenovirus injection into the tail vein. Adenovi-
rus gene transfer revealed ectopic overexpression of adi-
ponectin in the liver to markedly upregulate serum
adiponectin (control construct: 14.4  0.6 g/ml and
adiponectin construct: 44.5  4.9 g/ml) (Fig. 8B). In
particular, mainly the HMW and LMW forms of adiponec-
tin were increased (Fig. 8C). As shown by immunoblotting
of skeletal muscles, FHC expression in these muscles was
increased 2.5-fold in adiponectin-transferred mice (Fig.
8A) (i.e., in vitro experiments conﬁrmed FHC upregulation
under physiological conditions).
DISCUSSION
Intensive previous studies (5,8) revealed adiponectin to
improve insulin sensitivity and increase fatty acid oxida-
tion in skeletal muscles. In fact, MMW or HMW adiponec-
tin exerts these effects on skeletal muscles by activating
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FIG. 4. Effects of recombinant human adiponectin, TNF-, and free fatty acids on NF-B–regulated gene expressions in HUVECs. After pretreating
HUVECs with or without 100 mol/l BAY11-7082 for 1 h, 25 g/ml of adiponectin (A) or 10 ng/ml of TNF- (B) were added, followed by incubation
for 12 h. After HUVECs had been pretreated with or without 25 g/ml of adiponectin for 1 h, 10 ng/ml of TNF- or 0.4 mmol/l palmitate was added,
followed by incubation for 12 h (C and D). Cell lysates from HUVECs were subjected to SDS-PAGE, followed by electrophoretic transfer to a
nitrocellulose membrane. Membranes were incubated for1ha troom temperature with antibody against ICAM-1 (A, B, and C) or FHC (D).
Detection was performed using an electrochemiluminescence chemiluminescent kit according to the manufacturer’s instructions. Representative
data (each bracket) from four independent experiments (two samples for each experiment) are presented. Values are means  SE. *Signiﬁcant
difference (P < 0.05) relative to ICAM-1 (A–C) and FHC (D) expressions in control cells in the absence of ligands. **Signiﬁcant difference (P <
0.05) relative to ICAM-1 expression (C) in paired control cells in the absence of adiponectin but in the presence of palmitate (lane 3) or TNF-
(lane 5). N.S., not signiﬁcant relative to FHC expression in control cells in the absence of adiponectin (A), TNF- (B), and each ligand (D).
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tor–activated receptor- (26). On the other hand, HMW
adiponectin was previously reported to activate NF-B
(10), the master coordinator of immunity, inﬂammation,
differentiation, and cell survival (17,27–29). However, the
physiological role of NF-B activation in skeletal muscle
cells has yet to be elucidated. In the present study, we
treated murine primary cultured skeletal muscle cells with
recombinant adiponectin and found FHC to be signiﬁ-
cantly increased. The two-dimensional gel electrophore-
sis–based proteomic approach used herein is generally
acknowledged to be relatively insensitive in that it mea-
sures only a limited subset of tissue proteins and system-
atically excludes several classes. Adiponectin-induced
FHC upregulation was seen only in cultured skeletal
muscle cells, not endothelial cells (i.e., HUVECs). Judging
from the small increase in ICAM-1 expression with adi-
ponectin incubation, the NF-B–activating effect of adi-
ponectin was likely to be so small that we were unable to
demonstrate FHC upregulation in HUVECs. These re-
sponse differences between skeletal muscle and endothe-
lial cells may be explained by variations in adiponectin
species or different tissue localizations of molecules in-
volved in adiponectin signaling, such as adiponectin
receptors.
Our results demonstrate NF-B activation to be involved
in FHC upregulation by adiponectin. This mechanism of
FHC upregulation is supported by the following data. First,
in agreement with prior studies (10), we demonstrated
that adiponectin does, in fact, really phosphorylate and
degrade IB- in cultured skeletal muscle cells, thereby
enhancing NF-B activation. Second, FHC is regulated by
NF-B activation in response to enhanced oxidative stress
(30). Third, FHC induction in response to adiponectin
incubation is completely inhibited by BAY11-7082, an
inhibitor of IB- phosphorylation, or NF-B SN50, an
inhibitor of NF-B translocation into the nucleus. Though
cAMP-dependent induction of FHC was previously dem-
onstrated in human HeLa cells (31), our results show
clearly that the cAMP/PKA pathway is not involved in FHC
upregulation by adiponectin. Further study is needed to
clarify the precise mechanisms by which FHC is regulated.
Ferritin is a major intracellular iron-storage protein that
sequesters excess free iron molecules to minimize the
generation of iron-catalyzed ROS (30,32). Ferritin consists
of two subunits, FHC and FLC (15), and there are func-
tional differences between these subunits. FHC has fer-
roxidase activity (i.e., the oxidation of Fe
2 to Fe
3),
which is involved in rapid iron uptake and release and is
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tion in C2C12 myotubes and HUVECs exposed to oxidative stresses. A:
HUVECs, transfected with adenovirus overexpressing LacZ or recom-
binant FHC, were treated with 5.4  10
9 mol/l iron (II) sulfate
heptahydrate and 25 mmol/l glucose. B: C2C12 myotubes, transfected
with adenovirus overexpressing LacZ or recombinant FHC, were
treated with 20 ng/ml of TNF- and 100 mol/l 4-hydroxynonenal
(HNE). After a 24-h incubation, ROS generations were assayed by
CM-H2DCFDA oxidation-based ﬂuorescence. Representative results
from three independent experiments are presented. Values are
means  SE. *Signiﬁcant difference (P < 0.05) relative to ROS
production by paired control cells in the absence of FHC overexpres-
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FIG. 6. FHC, MnSOD, and iNOS mRNA levels in primary skeletal muscle
cells (A) and C2C12 myotubes (B) were determined by quantitative
PCR using an ABI PRISM model 7000 according to the manufacturer’s
instructions. Each column shows the mean  SE obtained from four
samples in the presence or absence of adiponectin. *Signiﬁcant differ-
ence (P < 0.05) relative to control cells in the absence of adiponectin.
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FLC has no ferroxidase activity but is likely to contribute
to stabilization of assembled ferritin proteins for long-term
iron storage (33). AP-1 motifs or NF-B–responsive ele-
ments have been found in the promoter region of FHC
(22,34) but not in that of FLC. Indeed, our results revealed
only the expression of FHC (i.e., not that of FLC) to be
increased in response to adiponectin exposure. In addition
to this iron-mediated regulation, ferritin is regulated by
immune/inﬂammatory cytokines. For example, similar
changes in FHC-to-FLC ratios (i.e., increased FHC with no
signiﬁcant change in FLC expression) were observed in
myoblasts following cytokine stimulation (35). Serum lev-
els of ferritin were previously reported to be increased in
patients with nonalcoholic steatohepatitis (36) or type 2
diabetes with obesity (37), disorders characterized by
inﬂammation in the liver or adipose tissues. In these
conditions, NF-B plays a pivotal role in cytokine-induced
FHC upregulation (17).
In recent decades, studies of NF-B have concentrated
mainly on discovering the molecules and biochemical
processes essential to the signaling cascades controlling
NF-B activity, since NF-B is known to be one of the
critical transcription factors mediating inﬂammatory cel-
lular responses, such as the production of cytokines and
adhesion molecules (36,38). However, recent studies have
focused on elucidating the novel mechanism whereby
NF-B exerts a protective effect against cytotoxicity. No-
tably, Pham et al. (17) discovered how NF-B antagonizes
TNF-induced apoptosis. They identiﬁed FHC as a crit-
ical mediator of NF-B protective activity against TNF-
induced cytotoxicity and concluded that FHC mediates
suppression of ROS accumulation, which in turn prevents
persistent activation of the Jun NH2-terminal kinase path-
way, thereby inhibiting apoptosis. Thus, in adiponectin-
sensitive tissues, such as skeletal muscle cells, FHC
upregulation induced by adiponectin plays a pivotal role in
the antagonistic cross-talk between the NF-B and ROS/
Jun NH2-terminal kinase pathways.
The physiological roles of NF-B in skeletal muscles are
currently unknown despite the well-recognized increase in
NF-B activity with acute exercise and muscle contrac-
tion (39). However, given the array of NF-B target gene
products in skeletal muscles, NF-B is speculated to
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FIG. 8. Effects of adiponectin overexpression on FHC regulation in skeletal muscles. Mice were systemically injected with recombinant adenovirus
expressing LacZ (L group) or adiponectin (A group) via the tail vein. Three days after virus infection, we conﬁrmed increased serum adiponectin levels,
using a mouse/rat adiponectin enzyme-linked immunosorbent assay kit (B) and by immunoblot analysis (C) and quantitatively analyzed FHC
expression in total hindlimbs (A), as previously described (19). Representative data of three mice (A) or one mouse (C) from each group are presented.
Each column shows the means  SE obtained from seven animals in each group. *Signiﬁcant difference (P < 0.05) relative to L group.
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cause stress factors accumulate with exercise and mus-
cle contraction (40). Along with FHC, MnSOD and iNOS
were demonstrated to be increased and to be targets of
the NF-B gene product. Thus, our results suggest
adiponectin to support NF-B activation and thereby
produce beneﬁcial effects in skeletal muscle by reducing
ROS via FHC upregulation.
In conclusion, we have clariﬁed that NF-B–targeted
genes were upregulated by adiponectin in skeletal mus-
cle cells, making this report, to our knowledge, the ﬁrst
ever demonstration of this property of adiponectin.
Taking into consideration that ROS activity is subject to
negative feedback regulation by NF-B, adiponectin
plays key roles in reducing oxidative stress and in
cytoprotection against ROS in skeletal muscles. In fact,
previous studies (41,42) have demonstrated a close
relation between oxidative stress and insulin resistance.
Thus, ROS production, following the accumulation of
excessive fat, may account for the link between obesity
and insulin resistance. Considering the beneﬁcial effects
of adiponectin on obesity-linked insulin resistance, FHC
upregulation by adiponectin may play an important role
in the mechanism by which adiponectin improves insu-
lin resistance.
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